NKAPD1: A Non-Coding RNA Molecule with Potential as A Cancer Drug Target and Biomarker

Target Name: NKAPD1

NCBI ID: G55216

NKAPD1

NKAPD1: A Non-Coding RNA Molecule with Potential as A Cancer Drug Target and Biomarker

NKAPD1 (C11orf57) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology have made it an attractive target for researchers to study, and recent studies have shed light on its role in various biological processes.

NKAPD1 is a novel RNA molecule that was discovered through a screening process for potential biomarkers and drug targets. It is characterized by its unique structure, which consists of a 134-amino acid protein that is attached to a 240-base pair RNA molecule. This unique structure allows NKAPD1 to interact with various molecules and participate in various biological processes.

One of the key features of NKAPD1 is its ability to interact with the protein PD-L1. PD-L1 is a protein that is expressed in many different types of cancer and has been linked to the development and progression of these diseases. NKAPD1 has been shown to interact with PD-L1 and can inhibit its activity, which may have implications for cancer treatment.

Another potential mechanism by which NKAPD1 may be involved in cancer treatment is its ability to regulate the expression of cancer-related genes. Many cancer-related genes are expressed at high levels and can contribute to the development and progression of these diseases. NKAPD1 has been shown to regulate the expression of several cancer-related genes, including the genes that are responsible for cell growth, division, and survival.

In addition to its potential role in cancer treatment, NKAPD1 has also been shown to have potential as a biomarker. Its unique structure and biology make it an attractive target for researchers to study, and its ability to interact with various molecules and participate in various biological processes may have implications for the development of new diagnostic tests or therapies.

NKAPD1 has been shown to interact with several other molecules, including the protein PD-L1, which has been linked to the development and progression of many different types of cancer. This interaction may have implications for the development of new cancer treatments that target PD-L1.

In addition to its potential role in cancer treatment, NKAPD1 has also been shown to have potential as a biomarker. Its unique structure and biology make it an attractive target for researchers to study, and its ability to interact with various molecules and participate in various biological processes may have implications for the development of new diagnostic tests or therapies.

Overall, NKAPD1 is a promising molecule for the development of new cancer treatments. Its unique structure and biology make it an attractive target for researchers to study, and its ability to interact with various molecules and participate in various biological processes may have implications for the development of new diagnostic tests or therapies. Further research is needed to fully understand its role in cancer biology and its potential as a drug target.

Protein Name: NKAP Domain Containing 1

The "NKAPD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NKAPD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets